| Dr Teresa Dianne Correia, PSYD | |
|
500 Cadmus Ln Ste 203, Easton, MD 21601-4094 | |
| (410) 873-2050 | |
| Not Available |
| Full Name | Dr Teresa Dianne Correia |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 10 Years |
| Location | 500 Cadmus Ln Ste 203, Easton, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467758086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 0810005375 (Virginia) | Secondary |
| 103T00000X | Psychologist | 06377 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chase Brexton Health Services Inc | 5395644835 | 85 |
News Archive
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.115-123, researchers Bishwajit Ghose and Sanni Yaya of the Faculty of Social Sciences, School of International Development and Global Studies University of Ottawa, Ottawa, ON, Canada, describe how this study is the first to assess the effect of socioeconomic status on blood pressure-controlling behavior among adult women with hypertension in Ghana.
Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.
Teenagers with autism spectrum disorder are in a bind. The disorder is characterized by impairments in communication and social interaction, but it's a continuum, so some teens diagnosed with ASD are considered high functioning and healthy enough to be "mainstreamed" in school.
Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.
› Verified 6 days ago
| Entity Name | Chase Brexton Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588606305 PECOS PAC ID: 5395644835 Enrollment ID: O20040512000520 |
News Archive
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.115-123, researchers Bishwajit Ghose and Sanni Yaya of the Faculty of Social Sciences, School of International Development and Global Studies University of Ottawa, Ottawa, ON, Canada, describe how this study is the first to assess the effect of socioeconomic status on blood pressure-controlling behavior among adult women with hypertension in Ghana.
Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.
Teenagers with autism spectrum disorder are in a bind. The disorder is characterized by impairments in communication and social interaction, but it's a continuum, so some teens diagnosed with ASD are considered high functioning and healthy enough to be "mainstreamed" in school.
Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Teresa Dianne Correia, PSYD 5903 Mount Eagle Dr Apt 214, Alexandria, VA 22303-2526 Ph: (203) 232-0203 | Dr Teresa Dianne Correia, PSYD 500 Cadmus Ln Ste 203, Easton, MD 21601-4094 Ph: (410) 873-2050 |
News Archive
In the current issue of Family Medicine and Community Health (Volume 6,Number 3, 2018, pp.115-123, researchers Bishwajit Ghose and Sanni Yaya of the Faculty of Social Sciences, School of International Development and Global Studies University of Ottawa, Ottawa, ON, Canada, describe how this study is the first to assess the effect of socioeconomic status on blood pressure-controlling behavior among adult women with hypertension in Ghana.
Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.
Teenagers with autism spectrum disorder are in a bind. The disorder is characterized by impairments in communication and social interaction, but it's a continuum, so some teens diagnosed with ASD are considered high functioning and healthy enough to be "mainstreamed" in school.
Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.
› Verified 6 days ago
Dr. Elizabeth C Koprowski, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 18 N Hanson St, Mill Place Ii, Suite 1, Easton, MD 21601 Phone: 410-822-3188 Fax: 410-820-4571 | |
Miss Wendy Sue Kraus, MA Psychologist Medicare: Not Enrolled in Medicare Practice Location: 114 North Washington St, Suite 25 30, Easton, MD 21601 Phone: 410-822-5007 Fax: 410-822-5569 | |
Dr. Richard R Greenbaum, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 8706 Commerce Dr, Easton, MD 21601 Phone: 410-820-7286 | |
Dr. Thomas R Bach, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 29897 Peirce Way, Easton, MD 21601 Phone: 410-822-8609 Fax: 410-822-8646 | |
Dr. Virginia B Blatchley, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 28421 Pinehurst Cir, Easton, MD 21601 Phone: 410-310-4721 Fax: 410-819-0524 | |
Toni Marie Repa, MS, EDS, NCSP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 29649 Meadow Gate Dr, Easton, MD 21601 Phone: 717-364-4981 |